BNF:

Not listed

Status:

Do Not Prescribe (DNP), Red

Decision Date:

August 2018

Comments

RED^1,2,3,8: NICE TA528 -  maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

RED^1,2,3,8: NICE TA784- maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. (Decision date - May 2022) NHSE commissioned

RED NICE TA1129: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (Decision date March 2026)

DNP: NICE TA1032: (Terminated Appraisal) Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (decision date Feb 2025)

 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again